Eagle Pharmaceuticals ( (EGRX) ) just unveiled an announcement.
The Company is actively exploring a variety of financial options to enhance its liquidity and solidify its capital structure, though the outcome and timeline of this process are uncertain, with no further updates promised unless legally or otherwise necessary. Despite amending its Credit Agreement multiple times, the Company has defaulted on its obligations to provide accurate, audited financial statements without qualifications. This default could lead to the Lenders enforcing their rights, which may include demanding immediate payment of outstanding loans or seizing the Company’s assets, significantly impacting the business. Discussions with the Lenders are ongoing, but the resolution remains uncertain.
See more insights into EGRX stock on TipRanks’ Stock Analysis page.
